Skip to main content

Table 1 Basal clinical characteristics in SGLT2i and control group

From: Effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on left ventricular remodelling and longitudinal strain: a prospective observational study

Variable SGLT2i (n = 30) Control (n = 22) p value
Female, n (%) 13 (43%) 10 (45%) 0.88
Age (years) 65.7 ± 8.7 68.2 ± 8.5 0.32
Arterial hypertension 18 (60%) 16 (73%) 0.34
Smokers 6 (20%) 1 (4%) 0.22
Dyslipidaemia 16 (53%) 12 (54%) 0.93
Coronary disease 3 (10%) 1 (4%) 0.33
Metformin 23 (77%) 18 (82%) 0.74
DPP4 inhibitors 8 (27%) 7 (32%) 0.68
Insulin 9 (30%) 5 (23%) 0.56
RAAS inhibitors 21 (70%) 17 (77%) 0.56
Beta-blockers 3 (10%) 2 (9%) 0.89
Aldosterone antagonist 2 (7%) 0 (0%) 0.50
GF ≥ 60 ml/min/1.73 m2 12 (43%) 11 (50%) 0.24
Glycated haemoglobin 7.78 ± 0.94 6.97 ± 0.44 0.002
Diabetes duration (months) 87 ± 97 128 ± 105 0.14
BMI (kg/m2) 30.5 ± 6.8 28.9 ± 4.7 0.33
GF (ml/min/1.73 m2) 92.6 ± 40.8 86.7 ± 28.9  
  1. DPP4 dipeptidyl peptidase-4, RAAS renin-angiotensin-aldosterone system, GF glomerular filtration, BMI Body Mass Index